SCHEMBL1734115

SCHEMBL1734115

COc1cccc(OC)c1-c1cc(C(N)=O)nc(S(C)(=O)=O)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 4/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MITF O75030 1/20 0.44
STAT3 P40763 1/20 0.44
HSP90AA1 P07900 3/20 0.43
HSP90AB1 P08238 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
KMT2A Q03164 3/20 0.42
TP53 P04637 2/20 0.42
HSD17B10 Q99714 1/20 0.42
PDE4B Q07343 1/20 0.41
ALDH1A1 P00352 3/20 0.39
SDHB P21912 2/20 0.39
CHRNA7 P36544 1/20 0.38
GLA P06280 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734400 0.88 LMNA (0.45) NPSR1LMNAHPGDHTTKDM4E
SCHEMBL1733451 0.86 HPGD (0.61) NPSR1LMNAHPGDHTTKDM4E
SCHEMBL1733454 0.78 HSP90AA1 (0.44) NPSR1HPGDKDM4EHSP90AA1HSP90AB1
SCHEMBL1734114 0.77 BPTF (0.57) NPSR1LMNAHPGDHTTKDM4E
SCHEMBL1734279 0.75 KDM4E (0.64) NPSR1LMNAHPGDKDM4EHSP90AA1
SCHEMBL11512311 0.68 LMNA (0.48) NPSR1LMNAHTTSMN1; SMN2TP53
SCHEMBL21296194 0.67 SCN9A (0.49) HPGDALDH1A1
SCHEMBL2816888 0.67 HSP90AA1 (0.52) NPSR1LMNAHPGDHTTKDM4E
SCHEMBL1733437 0.65 ADORA3 (0.44) NPSR1LMNAHPGDHTTKDM4E
SCHEMBL17821166 0.65 ALDH1A1 (0.48) HPGDKDM4EKMT2APDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP disclosed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP disclosed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO disclosed
CN-101223146-A Modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2008-07-16 CN disclosed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 NPSR1 3866/4885LMNA 3617/4885HPGD 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.